Allogene Therapeutics (ALLO) Appoints Stephen Mayo to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
July 12, 2022 8:30 AM EDTSOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, today announced the appointment of Stephen L. Mayo, Ph.D., a world renowned expert in computational protein design, to the companys Board of Directors.
We are privileged to have Dr. Mayo join our Board of Directors, said David Chang, M.D., Ph.D., President, CEO and Co-Founder of Allogene Therapeutics. His decades-long success record in both academia and the biopharmaceutical industry will... More
